Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax AML Observational Real-World Study of Treatment-naïve Patients Ineligible for Intensive Chemotherapy in Switzerland & Austria

NCT05215639 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05215639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax AML Observational Real-World Study of Treatment-naïve Patients Ineligible for Intensive Chemotherapy in Switzerland & Austria
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
December 27, 2021
Completion date
November 24, 2025
Enrollment
120 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia